Avantax Advisory Services Inc. Has $9.69 Million Position in Danaher Corporation $DHR

Avantax Advisory Services Inc. increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 12.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,031 shares of the conglomerate’s stock after buying an additional 5,390 shares during the period. Avantax Advisory Services Inc.’s holdings in Danaher were worth $9,686,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Nuveen LLC bought a new stake in shares of Danaher in the first quarter worth $833,941,000. Generation Investment Management LLP lifted its holdings in Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after buying an additional 1,787,522 shares during the period. Invesco Ltd. grew its position in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. increased its stake in shares of Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after buying an additional 1,072,617 shares during the period. Finally, Parnassus Investments LLC raised its position in shares of Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DHR has been the topic of several analyst reports. Redburn Partners set a $220.00 target price on shares of Danaher in a research report on Wednesday, October 8th. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. UBS Group lowered their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, July 23rd. Barclays upped their price target on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Finally, TD Cowen lifted their price objective on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 29,728 shares of company stock worth $6,448,990. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $220.41 on Tuesday. The business has a 50-day simple moving average of $206.07 and a 200 day simple moving average of $201.28. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The firm has a market capitalization of $155.69 billion, a price-to-earnings ratio of 45.45, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter last year, the firm posted $1.71 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. On average, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s payout ratio is 26.39%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.